Close Menu

This story has been updated to correct a company mistake. The firm had previously said it would continue marketing its COVID-19 test without FDA authorization.  

NEW YORK — Meridian Bioscience said on Tuesday that it has withdrawn its Emergency Use Authorization application to the US Food and Drug Administration for its Revogene SARS-CoV-2 test in order to conduct additional studies on the assay.

To read the full story....

...and receive Daily News bulletins.

Already have a 360Dx or GenomeWeb account?
Login Now.

Don't have a 360Dx or GenomeWeb account?
Register for Free.

Mar
18
Sponsored by
Thermo Fisher Scientific

Viruses mutate as they strive to thrive in response to selective pressures.

Mar
29
Sponsored by
Thermo Fisher Scientific

Global genetic surveillance is vital for understanding the evolution of viral pathogens and monitoring for changes in transmissibility, virulence, disease pathology, and impact on the efficacy of diagnostic tests, therapeutics, and vaccines.

Mar
31
Sponsored by
MilliporeSigma

This webinar will outline the development and commercialization journey of a novel CRISPR-based SARS-CoV-2 test.